Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
jammy32, in general, some people are unable to stop complaining. For example, even after the UK approves the MAA for DCVax-L, many will easily find something else to complain about. There will always be complainers among us. If you have this type of personality, then be careful not to set the bar too low for yourself.
A photo was posted on Twitter ($NWBO), and the slides have been requested…
jammy32, the arrow for the drop-down menu next to the list of Chairs may not be visible when using certain devices, but you should be able to search her name and access the information. I’m catching up on posts and see that you already found it.
Hang in there. It shouldn’t be another decade.
Splinters?
I’ll take poor word choice for $1000.
LOL, but I’m betting Viking didn’t make that up.
Some investors will be on their yachts incessantly whining about how long it took to get there.
Gary, I hope that’s the way LL and company planned it. I believe it would play out perfectly and would definitely get the job done. Regards, Vince
FeMike, I’ve been in this since 2013. In the past, when the company shared anything other than a completed milestone, they would get sued. So even after the JA quiet period is over, I’m content to wait for however long it takes until a RA, approves, a possible partnership/BO is announced, or some other significant event is completed. I don’t believe that they are tight-lipped because they don’t care about shareholders. No, quite the opposite. IMO it’s because they are looking out for all parties’ interests. But I don’t think your scenario will materialize anyway. I think we’ll have some good news prior to the ASM and any proxy vote for additional shares. My wife tells me an area for personal improvement is my lack of patience, but when it comes to NWBO, I’m very patient. Deep down I really think UK approval is imminent.
What about NWBO?
Bob, if that scenario plays out, why would anyone vote to deny the company needed working capital and thereby increase the risk of losing their investment rather than have their shares be diluted? Certainly the share price would go down further if more shares aren’t approved. Please help me understand the logic here. Is the intent to force LP to come up with alternative solution, and if so, what might that be? I understand why someone might be angry and frustrated, but I can’t wrap my mind around why they would make it more difficult for the company to succeed.
That pretty much sums it up.
I got back in at $1.20 several weeks ago.
Absent BO or P, I would agree.
I am an online ESL tutor for this Iranian-American materials engineer out in California. After I told him about NWBO, he did a deep dive. The other day he basically came to the same conclusion as you have. He said they must be waiting for something and thought shares would be at least $15-20 upon approval in the UK.
Institutional investors increased holdings by +13.62% last quarter, based on disclosures of 11 investors. https://www.msn.com/en-us/money/
Endpoints that have been met cannot be unmet because journal article authors can’t agree on the final draft.
The Dutch have a good sense of humor. As I was returning to my hotel room in Amsterdam to get something I’d forgotten the concierge commented, “Like my mother used to say, if you don’t use your brain, you have to use your legs.”
The numerous threads recently posted concerning approval timelines in the UK have been excellent. Thanks to all who contribute.
All sarcasm aside, I believe he’s referring to a financial report.
Perfect. Thank you, Onco.
crude, hopefully the following statement from their June 9, 2022 PR addresses your concern: We recently completed the acquisition of EPI Health. EPI Health equips us with a robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams. Following the acquisition, we employ approximately 100 staff, including sales personnel currently covering 42 territories, and we promote products for plaque psoriasis, rosacea, acne and dermatoses. We also have a pipeline of potential product candidates using our proprietary nitric oxide-based technology platform, NITRICIL™, to generate new treatments for multiple indications.
Good question. I see Hoff already covered it. GL.
Tote bag. It even sounds funny. But neither the tote bag scandal nor the generic name saga will likely survive script editing.
tryn2, someone posted that obtaining a generic name is a prerequisite for any drug that is to be marketed after regulatory approval, or something to that effect.
Senti won Best Generic Name with lydencel.
Then let’s make it Adamsindaholdencel.
In the Holdencel family, Biwaitdencel
Great minds…
Bob, if I had to communicate an estimate of an event that I thought would happen in approximately 18 months, I could see myself saying “in coming months”. I definitely wouldn’t say “in coming years”. If I were a CEO, I doubt that I would say “in about 18 months” in this context because there are so many things that could cause delays that are out of my control.
My guess is that if the committee of statisticians drafting the applications for the RAs have access to the unblinded data, then they would be able to include additional data analysis that hasn’t been presented so far at the conferences. Would a JA publication assist the DMC folks in writing the application and increase the likelihood of approval? I don’t know. Maybe so, but not so much as to affect the outcome.
That could be better for shareholders as long as it’s a happy ending. If IWD/Dr. Zivic’s notion is correct, then we may wake up one day to $10 pps after approval rather than $3 after the journal article is published. This is a much better scenario for longs who decide to take some profit in the near-term. If this is how it plays out, I hope LP has another loan with favorable terms lined up so that she can push the proxy vote for the increase in AS until after the first RA approval. The wait won’t be fun, but it’ll be worth it.
Shot in the dark: July 28, 2022.
A possible explanation may be related to the fact that physicians routinely take advantage of opportunities to be listed as authors, presenters, or contributors on articles, conferences, etc. for the sake of the recorded achievement.
HL, are you sure? I think the buying BP shareholders would certainly be made aware of future estimated earnings prior to any BO proxy vote. Who wouldn’t support a BO price that’s much higher than the usual multipliers when they’re being informed that the transaction is estimated to increase the BP share price by even higher multiples. If ever there were an exception to a rule, NWBO fits the bill considering the DCVax platform’s potential and the likelihood of it being part of SOC for many types of cancers.
scotty, this isn't a sewing circle.
I’m still here. I got a little lucky on this one, which doesn’t happen often, as I sold at a small loss after the PR about the BLA submission didn’t move the SP much. I had plans to get back in closer to FDA approval, and if a BO were to be announced prior, I was prepared to miss out on it. Now I just see this as a delayed entry point date. I can identify with those who are holding as I’ve been in NWBO for a very long time.
The elephant in the room.
The journal may be allowing the same NYAS presentation if it has been coordinated in advance.